BIOMARIN PHARMACEUTICAL INCBB

BIOMARIN PHARMACEUTICAL INC

66.10EURR
−0.42−0.63%
At close at 20:14 GMT
EUR
No trades
See on Supercharts

BM8 fundamentals

Key facts

Market capitalization‪12.66 B‬EUR
Founded1997
Employees (FY)‪3.04 K‬
CEOAlexander Hardy
About

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Ownership
‪‪190.78 M‬‬
Free Float shares
‪‪188.34 M‬‬ (98.72%)
Closely held shares
‪‪2.44 M‬‬ (1.28%)
Free Float shares
‪‪188.34 M‬‬ (98.72%)
Closely held shares
‪‪2.44 M‬‬ (1.28%)
Capital structure
Market cap
‪‪12.66 B‬‬
Debt
‪‪627.37 M‬‬
Cash & equivalents
‪‪1.10 B‬‬
Enterprise value
‪‪12.19 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪12.66 B‬‬
Price to earning ratio (P/E)
32.14x
Price to sales ratio (P/S)
4.89x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
32.14x
Price to sales ratio (P/S)
4.89x
Valuation ratios
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪30.00‬
‪60.00‬
‪90.00‬
‪120.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪3%‬
‪7%‬
‪11%‬
‪15%‬
‪19%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Innovative Therapies
By country
Period: 2024
United States
Europe
Rest of World
Latin America
Global

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Actual
Estimate
Earnings
Next:Apr 23, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.17‬
‪0.34‬
‪0.51‬
‪0.68‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

BM8 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−400.00 M‬‬
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
‪‪4.00 B‬‬
Assets
Liabilities